Abstract:Objectives: Roflumilast is indicated for patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). Information on the prevalence and risk of diarrhea, the most reported adverse event in clinical trials, among patients initiating roflumilast in real-world settings is limited. Methods: We selected patients aged $40 years with COPD who were new users of roflumilast and the active comparator group, triple therapy (inhaled corticosteroids (ICS), long acting beta agonists (LABA) and long acting … Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.